Dudediligence.

Inhibikase Therapeutics, Inc

IKTNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

132.0M

on 2026-06-30, from 6.48M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

50M100MMar2024JunSepDecMar2025JunSepDec$1.45Mar2026Jun

Newest

$300.0M

S-3 of 2025-06-20. 1 prospectus supplement filed under it since. S-3 ↗

$185.0M

Jefferies, agreement of 2025-06-20. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-11 is not read yet.

Cash

14.9 quarters

$159.0M on 2026-06-30 ÷ $10.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-11-20Public offering incl. 22.87M pre-funded68,965,518$1.45$100.0M424B5 ↗